Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.

ABSTRACT:

Objective

To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma).

Methods

Eighteen patients with diffuse SSc of ResultsThe baseline characteristics of the patients were similar in both groups (n=9 in each). One patient in the rapamycin group who never received the study dr

SUBMITTER: Su TI 

PROVIDER: S-EPMC2841149 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature